IN2012DN03217A - - Google Patents

Download PDF

Info

Publication number
IN2012DN03217A
IN2012DN03217A IN3217DEN2012A IN2012DN03217A IN 2012DN03217 A IN2012DN03217 A IN 2012DN03217A IN 3217DEN2012 A IN3217DEN2012 A IN 3217DEN2012A IN 2012DN03217 A IN2012DN03217 A IN 2012DN03217A
Authority
IN
India
Prior art keywords
compounds
compositions containing
kinase
pain
cancer
Prior art date
Application number
Inventor
Mustapha Haddach
Fabirce PIERRE
Original Assignee
Cylene Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cylene Pharmaceuticals Inc filed Critical Cylene Pharmaceuticals Inc
Publication of IN2012DN03217A publication Critical patent/IN2012DN03217A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A61P33/12—Schistosomicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/10—Aza-phenanthrenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/16—Ring systems of three rings containing carbocyclic rings other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)

Abstract

The invention provides compounds that inhibit CK2 and/or Pim kinases and compositions containing such compounds. These tricyclic compounds and compositions containing them are useful for treating proliferative disorders such as cancer, as well as other kinase-associated conditions including inflammation, pain, pathogenic infections, and certain immunological disorders.
IN3217DEN2012 2009-09-16 2010-09-16 IN2012DN03217A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24310409P 2009-09-16 2009-09-16
PCT/US2010/049113 WO2011035019A1 (en) 2009-09-16 2010-09-16 Novel tricyclic protein kinase modulators

Publications (1)

Publication Number Publication Date
IN2012DN03217A true IN2012DN03217A (en) 2015-10-23

Family

ID=43757156

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3217DEN2012 IN2012DN03217A (en) 2009-09-16 2010-09-16

Country Status (13)

Country Link
US (1) US20110071136A1 (en)
EP (1) EP2477493A1 (en)
JP (1) JP2013505252A (en)
KR (1) KR20120104180A (en)
CN (1) CN102647904A (en)
AU (1) AU2010295619A1 (en)
BR (1) BR112012005970A2 (en)
CA (1) CA2774266A1 (en)
IL (1) IL218631A0 (en)
IN (1) IN2012DN03217A (en)
MX (1) MX2012003322A (en)
SG (1) SG179163A1 (en)
WO (1) WO2011035019A1 (en)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9335980B2 (en) 2008-08-15 2016-05-10 Apple Inc. Processing vectors using wrapping propagate instructions in the macroscalar architecture
US8583904B2 (en) 2008-08-15 2013-11-12 Apple Inc. Processing vectors using wrapping negation instructions in the macroscalar architecture
US9342304B2 (en) 2008-08-15 2016-05-17 Apple Inc. Processing vectors using wrapping increment and decrement instructions in the macroscalar architecture
US9335997B2 (en) 2008-08-15 2016-05-10 Apple Inc. Processing vectors using a wrapping rotate previous instruction in the macroscalar architecture
EP2785377A4 (en) * 2011-11-29 2015-07-08 Baylor College Medicine PROCESS FOR INCREASING COGNITION
US9389860B2 (en) 2012-04-02 2016-07-12 Apple Inc. Prediction optimizations for Macroscalar vector partitioning loops
CA2880896C (en) 2012-06-26 2021-11-16 Del Mar Pharmaceuticals Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof
CA2897200C (en) 2013-01-14 2021-07-06 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors
PE20191245A1 (en) 2013-01-15 2019-09-18 Incyte Holdings Corp THIAZOLCARBOXAMIDES AND PYRIDINACARBOXAMIDE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS
US9817663B2 (en) 2013-03-19 2017-11-14 Apple Inc. Enhanced Macroscalar predicate operations
US9348589B2 (en) 2013-03-19 2016-05-24 Apple Inc. Enhanced predicate registers having predicates corresponding to element widths
CN105492011A (en) 2013-04-08 2016-04-13 丹尼斯·M·布朗 Therapeutic potentiation of suboptimally administered chemical compounds
CN105658653A (en) 2013-08-23 2016-06-08 因赛特公司 Furo- and thieno-pyridine carboxamide compounds useful as PIM kinase inhibitors
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
US9822124B2 (en) 2014-07-14 2017-11-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors
CN112826940A (en) * 2014-11-11 2021-05-25 杭州多禧生物科技有限公司 Conjugates of cytotoxic molecules and cell-binding receptor molecules
TW201636329A (en) 2015-02-02 2016-10-16 佛瑪治療公司 Bicyclo[4,6,0]hydroxamic acid as HDAC inhibitor
ES2770123T3 (en) 2015-02-02 2020-06-30 Forma Therapeutics Inc 3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors
CA2975277A1 (en) 2015-03-04 2016-09-09 Dana-Farber Cancer Institute, Inc. Tricyclic kinase inhibitors of melk and methods of use
WO2016196244A1 (en) 2015-05-29 2016-12-08 Incyte Corporation Pyridineamine compounds useful as pim kinase inhibitors
JP6798494B2 (en) * 2015-07-27 2020-12-09 味の素株式会社 Method for producing cysteine derivative and cysteine sulfoxide derivative
AR105967A1 (en) 2015-09-09 2017-11-29 Incyte Corp SALTS OF A PIM QUINASA INHIBITOR
WO2017059251A1 (en) 2015-10-02 2017-04-06 Incyte Corporation Heterocyclic compounds useful as pim kinase inhibitors
IL287136B2 (en) 2016-02-05 2023-09-01 Denali Therapeutics Inc Inhibitors of receptor-interacting protein kinase 1
EP3472131B1 (en) 2016-06-17 2020-02-19 Forma Therapeutics, Inc. 2-spiro-5- and 6-hydroxamic acid indanes as hdac inhibitors
HUE058802T2 (en) 2016-12-09 2022-09-28 Denali Therapeutics Inc Compounds suitable as RIPK1 inhibitors
IL270900B2 (en) 2017-06-06 2024-12-01 Verrica Pharmaceuticals Inc Treatment of cutaneous disorders
US12290651B2 (en) 2017-06-15 2025-05-06 Verrica Pharmaceuticals Inc. Devices and methods for the treatment of body surface disorders
EP3661512A4 (en) * 2017-07-31 2020-12-30 The Regents of the University of California COMPOUNDS AGAINST CANCER / AGAINST FIBROSIS
JP7411545B2 (en) 2017-10-04 2024-01-11 ヴェリカ ファーマシューティカルズ インコーポレーテッド Synthesis of cantharidin
CN109761902B (en) * 2017-11-09 2022-06-10 四川大学 6-Panthridone derivatives and preparation method and use thereof
WO2019113487A1 (en) 2017-12-08 2019-06-13 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
US11071727B2 (en) 2018-01-26 2021-07-27 Northwestern University Therapeutic targeting of proteolytic cleavage of the mixed lineage leukemia gene product (MLL1) by taspase1 using kinase inhibitors
CA3116731A1 (en) 2018-10-19 2020-04-23 Senhwa Biosciences, Inc. Combinations for immune-modulation in cancer treatment
CN109369528B (en) * 2018-11-26 2022-03-04 天津医科大学 Trifluoromethyl-substituted cyclopentanonoquinoline compound and pharmaceutically acceptable salt, preparation method and application thereof
BR112022019558A2 (en) * 2020-03-30 2022-12-06 Senhwa Biosciences Inc METHOD FOR TREAT A HEPATOTROPIC VIRUS INFECTION, PHARMACEUTICAL COMPOSITION FOR TREAT A HEPATOTROPIC VIRAL INFECTION, AND, USE OF A COMPOUND
MX2022013657A (en) 2020-05-05 2023-02-01 Nuvalent Inc Heteroaromatic macrocyclic ether chemotherapeutic agents.
EP4146205A4 (en) 2020-05-05 2024-05-29 Nuvalent, Inc. HETEROAROMATIC MACROCYCLIC ETHER-BASED CHEMOTHERAPY AGENTS
CN113004294B (en) * 2021-03-08 2023-01-17 温州大学新材料与产业技术研究院 A kind of tetrahydrofuro and 1,4-dihydroquinoline compound and its preparation method and application
CA3231813A1 (en) 2021-10-01 2023-04-06 Sibao CHEN Solid forms, pharmaceutical compositions and preparation of heteroaromatic macrocyclic ether compounds
US11999750B2 (en) 2022-01-12 2024-06-04 Denali Therapeutics Inc. Crystalline forms of (S)-5-benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydropyrido [3,2-B][1,4]oxazepin-3-yl)-4H-1,2,4-triazole-3-carboxamide
DK4497438T3 (en) 2022-04-28 2025-09-29 Xinthera Inc TRICYCLIC PARP1 INHIBITORS AND THEIR USE
CN115819436B (en) * 2022-11-03 2023-09-05 淮阴师范学院 The preparation method of quinolinolane sulfolane derivatives
CN116947879B (en) * 2023-07-25 2025-10-31 沈阳药科大学 BBI608 derivative, preparation method thereof and application thereof in preparing medicines for treating STAT3 mediated diseases

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005028624A2 (en) * 2003-09-15 2005-03-31 Plexxikon, Inc. Molecular scaffolds for kinase ligand development
CA2974246C (en) * 2006-09-01 2020-02-25 Senhwa Biosciences, Inc. Tricyclic heteroaryl compounds and their use as protein modulators

Also Published As

Publication number Publication date
CN102647904A (en) 2012-08-22
CA2774266A1 (en) 2011-03-24
WO2011035019A1 (en) 2011-03-24
BR112012005970A2 (en) 2015-09-08
EP2477493A1 (en) 2012-07-25
US20110071136A1 (en) 2011-03-24
MX2012003322A (en) 2012-07-23
SG179163A1 (en) 2012-05-30
IL218631A0 (en) 2012-05-31
KR20120104180A (en) 2012-09-20
JP2013505252A (en) 2013-02-14
AU2010295619A1 (en) 2012-05-10

Similar Documents

Publication Publication Date Title
IN2012DN03217A (en)
IN2012DN03213A (en)
IN2012DN03112A (en)
MX2011012369A (en) Pyrazolopyrimidines and related heterocycles as kinase inhibitors.
MX2020009223A (en) Afucosylated anti-fgfr2iiib antibodies.
MY188363A (en) Substituted tricyclic compounds as fgfr inhibitors
EP4230264A3 (en) Prodrugs of fumarates and their use in treating various deseases
NZ722326A (en) Tricyclic compounds as anticancer agents
MX2015014947A (en) Substituted5-(3,5-dimethylisoxazol-4-yl)indoline-2-ones.
WO2012170827A3 (en) Pyrazolopyrimidines and related heterocycles as ck2 inhibitors
JO2788B1 (en) Amidophenoxyindazoles useful as inhibitors of c-met
MX2009008347A (en) Oxabicycloheptanes and oxabicycloheptenes, their preparation and use.
ZA201907613B (en) Dosage regimes for the administration of an anti-cd19 adc
PH12014501061B1 (en) Tricyclic compounds, compositions comprising them and uses thereof
AU2018253600A1 (en) Dosage forms and therapeutic uses of l-4-chlorokynurenine
TN2017000256A1 (en) Substituted pyridyl-cycloalkyl-carboxylic acids, compositions containing them and medical uses thereof
MX2016009056A (en) Compositions and methods for treatment of abnormal cell growth.
EA202190041A1 (en) DOSING SCHEDULES FOR ADC K CD19 ADMINISTRATION
TN2011000013A1 (en) Amidophenoxyindazoles useful as inhibitors of c-met
HK1230956A1 (en) Compositions and methods for treatment of abnormal cell growth
WO2015024000A3 (en) Mitochondrially-targeted electrophilic compounds for cancer treatment
PH12016502133A1 (en) Substituted tricycle compounds as fgfr inhibitors